Retatrutide, by Soma Corp., is gaining increasing attention as a innovative treatment for metabolic control . This dual-action drug combines the properties of a GLP-1 receptor activator and a GIP receptor activator , designed to not only promote reduced body fat but also improve associated metabolic conditions . Initial patient trials have demonstr